first announcement - CIRSE.org

54 Scientific Programme
15:45 - 16:45
Session 48 Workshops
48.1 Carotid stenting: Getting started Aula Magna
S. Macdonald (Glasgow/UK), B.E. Cil (Ankara/TR)
48.2 Closure device: When, how and what device Room C
S. Müller-Hülsbeck (Kiel/DE), S. Lyon (Victoria/AU)
48.3 Advanced venous acces Room I
A.F. Watkinson (Exeter Devon/UK), S. Trerotola (Philadelphia/US)
48.4 Post Partum haemorrhage: Prevention and treatment Room G
A.C. Roberts (La Jolla/US), H.T. Abada (Cergy-Pontoise/FR)
48.5 Lung and renal RF Room B
J. Palussière (Bordeaux/FR), D. Dupuy (Providence, RI/US)
48.6 Thoracic stenting: How I do it Room H
R.A. Morgan (London/UK), M.D. Dake (Charlottesville, VA/US)
48.7 EVAR: Patient selection, technique and follow-up protocols Room F
C. Vignali (Pisa/IT), M. Szczerbo-Trojanowska (Lublin/PL)
48.8 Intervention in severe acute pancreatitis Room D
O. Akhan (Ankara/TR), P.C. Rowlands (Liverpool/UK)
48.9 IVC Filters Room E
T.B. Kinney (San Diego, CA/US), M.J. Lee (Dublin/IE)
17:00 - 18:30
Session 49.1 Free Papers
Liver Tumors (vascular therapies) Room C
Chairmen: B. Wood (Bethesda, MD/US), M. Okazaki (Fukuoaka/JP)
Annual Meeting and Postgraduate Course
49.1.1 Selective internal radiation therapy in patients with advanced hepatocellular carcinoma
A. Martinez de la Cuesta, J. Bilbao, B. Sangro, J. Boan, J. Rodriguez, J. Noguera; Pamplona/ES
49.1.2 Treatment of extensive metastatic liver disease with transarterial,
intrahepatic administration of Yttrium90 microspheres: toxicity assessment
T.F. Jakobs 1, R.-T. Hoffmann 1, A. Schmitz 1, K. Tatsch 1, W. Koch 1, T.K. Helmberger 2, M.F. Reiser 1;
1Munich/DE, 2Lübeck/DE
49.1.3 Sequential tanscatheter arterial chemoembolization and portal vein embolization
before major hepatectomy for patients with hepatocellular carcinoma
D.C. Madoff, E.K. Abdalla, M.J. Wallace, R. Murthy, K. Ahrar, S. Gupta, S.H. Wei, M.E. Hicks, J.-.N. Vauthey; Houston/US
49.1.4 Treatment of unresectable hepatocellular carcinoma using intra-arterial Yttrium-90: long-term follow-up
B. Atassi, R. Lewandowski, L. Kulik, M.F. Mulcahy, R.A. Omary, R. Salem; Chicago/US
49.1.5 Transarterial chemoembolization of neuroendocrine hepatic metastases using drug-eluting beads
C. Teriitehau, T. de Baère, M. Abdel Rehim, F. Deschamps; Villejuif/FR
49.1.6 Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma
with inferior vena cava and right atrium tumors
M.-C. Chern, V.P. Chuang, T.-I. Cheng; Taipei/TW
49.1.7 Preoperative chemoembolization in Patients with hepatocellular carcinoma undergoing
liver transplantation: influence of emergent versus elective procedures on patient survival
and tumor recurrence rate.
E.M. Walser, A.H. Stockland, R. Paz, J.M. McKinney, G.R. May; Jacksonville/US
49.1.8 Hepatocellular carcinoma chemoembolization with DC beads in 42 patients. Safety and efficacy
K. Malagari, E. Alexopoulou, K. Chatzimichail, T. Spyridopoulos, G. Economou, D. Letsou, V. Vergadis,
D. Antonopoulos, D.A. Kelekis, A. Gouliamos; Athens/GR
49.1.9 Radioembolism (Ittrium 90) of hepatic liver mets. Preliminary experience
R. Cianni, A. Satarelli, E. Notarianni, M. Iozzino, M. Coniglio; Latina/IT
49.1.10 "Best of SIR" - A radiogenomic analysis to identify imaging phenotypes associated
with drug response gene expression programs in HCC
M.D. Kuo, J. Gollub, C.B. Sirlin, C. Ooi; San Diego, CA/US
Cardiovascular and Interventional Radiological Society of Europe